Sign In
Buy PACB
$1.45
-0.180 (-11.04%)
At Close: Jun 05, 2026
PacBio Announces the Appointment of Chris Gibson to the Board of Directors
08:30am, Thursday, 05'th Mar 2026
Proven experience in leveraging AI in biology will strengthen the board of directors as PacBio develops data tools to maximize the power of HiFi sequencing Proven experience in leveraging AI in biolog
Head to Head Survey: Pacific Biosciences of California (NASDAQ:PACB) and NexGel (NASDAQ:NXGL)
01:10am, Thursday, 05'th Mar 2026
Pacific Biosciences of California (NASDAQ: PACB - Get Free Report) and NexGel (NASDAQ: NXGL - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contr
PacBio and DNAstack Collaborate on Global HiFi Genome Network Hub
11:15am, Tuesday, 03'rd Mar 2026
PACB teams with DNAstack to launch a global HiFi genome network, linking 10,000+ sequences to boost rare disease research without moving data.
PacBio and DNAstack Launch First Global Federated HiFi Whole Genome Dataset to Accelerate Rare Disease Research
09:05am, Tuesday, 24'th Feb 2026
Collaboration powers secure international data sharing through the HiFi Solves Global Consortium Collaboration powers secure international data sharing through the HiFi Solves Global Consortium
Pacific Biosciences of California (NASDAQ:PACB) Insider Sells $524,232.94 in Stock
04:32am, Sunday, 22'nd Feb 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) insider Christian Henry sold 331,793 shares of the firm's stock in a transaction on Tuesday, February 17th. The stock was sold
Genomics Stocks That Deserve a Place in Your Portfolio in 2026
11:51am, Friday, 20'th Feb 2026
Genomics and synthetic biology are reshaping healthcare, as rapid DNA sequencing advances power personalized medicine and strong market growth.
PacBio to Participate in the TD Cowen 46th Annual Health Care Conference
04:05pm, Wednesday, 18'th Feb 2026
MENLO PARK, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will participate
Pacific Biosciences of California, Inc. (PACB) Q4 2025 Earnings Call Transcript
07:27am, Saturday, 14'th Feb 2026
Pacific Biosciences of California, Inc. (PACB) Q4 2025 Earnings Call Transcript
PacBio Q4 Earnings and Revenues Beat Estimates, Gross Margin Up
11:25am, Friday, 13'th Feb 2026
PACB beats Q4 estimates as revenue jumps 14%, gross margin hits 41% and 2026 revenues are projected in the range of $165-$180M after strategic moves.
Pacific Biosciences of California (PACB) Reports Q4 Loss, Beats Revenue Estimates
06:35pm, Thursday, 12'th Feb 2026
Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.2 per share a year ago.
PacBio Completes Sale of Short-Read Sequencing Assets
09:05am, Monday, 02'nd Feb 2026
MENLO PARK, Calif., Feb. 02, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the completion of the sale of se
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Consensus Rating of “Hold” from Analysts
04:24am, Monday, 02'nd Feb 2026
Pacific Biosciences of California, Inc. (NASDAQ: PACB - Get Free Report) has been given an average recommendation of "Hold" by the seven brokerages that are presently covering the company, MarketBeat
Here's Why Pacific Biosciences of California (PACB) Fell More Than Broader Market
07:15pm, Friday, 30'th Jan 2026
In the most recent trading session, Pacific Biosciences of California (PACB) closed at $2.26, indicating a -4.64% shift from the previous trading day.
PacBio: The Consumables Flywheel Is Turning. The Chart Wants Confirmation
12:16pm, Wednesday, 28'th Jan 2026
Pacific Biosciences is transitioning to a recurring revenue model as consumables reach a record 55% of Q3 revenue, driving margin improvements. Non-GAAP gross margin hit 42% in Q3, with management att
PacBio to Report Fourth Quarter and Full Year 2025 Financial Results on February 12, 2026
04:05pm, Tuesday, 27'th Jan 2026
MENLO PARK, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter and full year 2025 financial r
